Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild to Moderate Atopic Dermatitis Clear all
Completed Phase 3 Interventional Results available

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

NCT00120523
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Topical corticosteroids
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
3 Months to 12 Months
Enrollment
2,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

NCT06309355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
YR001 ointment, Placebo
Drug · Other
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

NCT03356977
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 23 Months
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Hot Springs, Arkansas • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

NCT03268174
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
AO+Mist, Placebo
Other
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Not applicable Interventional

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

NCT04740892
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Wash IP, Cream IP
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
3 Months to 72 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
High Point, North Carolina • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

NCT02068352
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Vehicle ointment
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Jun 7, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

NCT03770858
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Scratch sensor
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871
View directory record Official record
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

NCT00076375
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Nanocrystalline silver cream (NPI)
Drug
Lead sponsor
Nucryst Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

NCT02949960
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DMT210 Topical Gel, Vehicle Control
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

NCT06673654
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03394677
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% ointment, Vehicle ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Los Angeles, California • Oklahoma City, Oklahoma • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Test the Effects of Arctiva on Mild to Moderate Eczema

NCT05918237
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Arctiva
Other
Lead sponsor
ClinOhio Research Services, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

NCT04040192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

NCT01232985
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
RD047-26
Device
Lead sponsor
Oculus Innovative Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

NCT04753034
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TER-101, Vehicle
Drug
Lead sponsor
Teres Bio, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Encinitas, California • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01826461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PDI-192, Vehicle
Drug
Lead sponsor
PreCision Dermatology, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
San Diego, California • Chicago, Illinois • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

NCT04156191
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Rancho Santa Margarita, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

NCT04664153
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment, Vehicle ointment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jun 7, 2026, 11:03 AM EDT
Recruiting No phase listed Observational

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

NCT06259669
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
958 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jun 7, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children

NCT00886587
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
F# 11054-010, F# 10495-053
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 12 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Colorado Springs, Colorado • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jun 7, 2026, 11:03 AM EDT
Not listed Phase 4 Interventional

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

NCT04214197
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Top Oint
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jun 7, 2026, 11:03 AM EDT